David Drewry

David Drewry, Ph.D., is an Associate Professor at the Structural Genomics Consortium UNC (University of North Carolina at Chapel Hill), affiliated with the UNC Eshelman School of Pharmacy. He is a leader in medicinal chemistry and kinase inhibitor design, with over 24 years of industry experience at GlaxoSmithKline and legacy companies. His research focuses on precompetitive chemical biology, kinase signaling networks, and open collaborative drug discovery strategies. Drewry earned his B.S. in Chemistry from Yale University and his Ph.D. from UC Berkeley under Paul Bartlett, studying zinc protease inhibitors.

Key projects include the Kinase Chemogenomic Set (KCGS), which provides kinase inhibitors for phenotypic screening; chemical probe development for understudied kinases (e.g., CAMKK2, CDKL5); and drug discovery targeting Brachyury in chordoma and Plasmodium kinases for malaria. His work bridges academia and industry to advance preclinical drug development.

Publications emphasize kinase inhibitors for malaria, kinase biology, and chemical probe development. Collaborations span academia, industry, and global health initiatives. Drewry’s efforts prioritize open science and translational research to address unmet medical needs in infectious diseases and cancer.